Rapid detection of Mycoplasma pneumoniae CARDS toxin in clinical respiratory specimens by a loop-mediated isothermal amplification assay
Open Access
- 5 March 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1496829
Abstract
In light of the absence of rapid and precise diagnostic laboratory tests for the detection of Mycoplasma pneumoniae (MP), a prominent etiological agent implicated in a range of respiratory infections, we developed and evaluated a rapid and straightforward loop-mediated isothermal amplification (LAMP) assay targeting the MP community-acquired respiratory distress syndrome toxin (CARDS TX) gene. The LAMP assay was performed at 65°C for a duration of 60 min, yielding a minimum detection concentration of MP CARDS TX at 0.4986 pg/μl. The assay exhibited no cross-reactivity with 13 other prevalent pathogens associated with respiratory infections or with other common bacterial toxin genes. To further substantiate the validity of the LAMP assay, 200 pharyngeal swabs or bronchoalveolar lavage (BAL) samples were collected from inpatients diagnosed with community-acquired pneumonia (CAP) between June 2021 and July 2022. The results were compared with those obtained by the quantitative real-time polymerase chain reaction (qPCR) method for verification purposes. Of the 200 clinical specimens, 11 exhibited positive results for MP by LAMP and 10 displayed positive results for MP by qPCR (P = 1.000). In summary, a sensitive, specific, straightforward, and expeditious LAMP method for CARDS TX identification was developed to facilitate rapid detection of MP in point-of-care settings. This assay enables early and accurate diagnosis, even in resource-limited environments, which is important for proper antibiotic treatment and prognosis of MP infection.Keywords
This publication has 41 references indexed in Scilit:
- Exploring the pathogenicity of Mycoplasma pneumoniae: Focus on community-acquired respiratory distress syndrome toxinsMicrobial Pathogenesis, 2024
- Disease burden and macrolide resistance of Mycoplasma pneumoniae infection in adults in the Asia-Pacific regionInternational Journal of Antimicrobial Agents, 2024
- Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictionsThe Lancet Microbe, 2023
- Mycoplasma pneumoniae CARDS toxin exploits host cell endosomal acidic pH and vacuolar ATPase proton pump to execute its biological activitiesScientific Reports, 2021
- Mycoplasma pneumoniae infection and risk of childhood asthma: A systematic review and meta-analysisMicrobial Pathogenesis, 2021
- Mycoplasma pneumoniae-related hepatitis in childrenMicrobial Pathogenesis, 2020
- Loop-mediated isothermal amplification (LAMP): Expansion of its practical application as a tool to achieve universal health coverageJournal of Infection and Chemotherapy, 2020
- Can sputum gram stain be used to predict lower respiratory tract infection and guide empiric antimicrobial treatment: Experience from a tertiary care hospitalJournal of Microbiological Methods, 2019
- Antimicrobial therapy of macrolide-resistantMycoplasma pneumoniaepneumonia in childrenExpert Review of Anti-infective Therapy, 2017
- Community-acquired pneumonia related to intracellular pathogensIntensive Care Medicine, 2016